European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya

View source ↗

Summary

EMA provides new guidance to better manage the risk of heart-related adverse effects with Gilenya (fingolimod).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)